Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

·

·

Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

Here’s some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (NASDAQ:MYL) and Biocon’s Semglee, which is essentially identical to Sanofi’s (NASDAQ:SNY) insulin product Lantus.
See Original Article

Williams awarded accounting scholarships

The Educational Foundation of the Kentucky Society of Certified Public Accountants has awarded $82,679 in scholarships to college students studying
See Original Article

IRS warns of coronavirus-related tax schemes

Accounting Today is putting together its VAR 100 ranking of the top value-added resellers of accounting and accounting-related software by revenue.
See Original Article

Charting the Global Economy: 2020 Seen as Worst Since WW II

Here are some of the charts that appeared on Bloomberg this week, offering insight into the latest developments in the global economy:
See Original Article

Bloomberg Best: Pandemic, Unrest and Investing (Podcast)

Host Denise Pellegrini features the best stories of the day from Bloomberg Radio, Bloomberg Television, and over 150 News bureaus around the
See Original Article



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.